MAR 1 5 2005 EX THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

TAS

Serial No.: 10/647,438

Group Art Unit: 1755

Filed: 8/26/03

Examiner: MANLOVE, Shalie A.

For: CALCIUM PHOSPHATE CEMENT COMPOSITION AND A METHOD FOR THE

PREPARATION THEREOF

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this inform disclosure statement is filed:		
	within three months of the filing date of a national application other than a CPA under § 1.53(d);	
	within three months of the actual filing date of the national phase of a PCT application; OR	
\boxtimes	before the mailing of a first substantive office action (including after filing of an RCE).	
Under specifi	37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periods ed in 37 C.F.R. § 1.97(b), but before the mailing date of:	
	a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR a notice of allowance under 37 C.F.R. § 1.311; and	

1

DOCKET NO.: MAIKO-0037

		is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).		
	Under date o	37 C.F f the fol	R. § 1.97(d), this information disclosure statement is filed after the mailing llowing actions which have not been withdrawn:		
		a final	action under 37 C.F.R. § 1.113;		
		termin	nation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
		OR a	notice of allowance under 37 C.F.R. § 1.311;		
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).		
Staten	nents U	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited]	Materia	<u>ls</u>	•		
		anceste	of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).		
			s of materials listed but not attached were cited in an international search dated		
		Not rec	quired by 37 CFR § 1.98.		
	\boxtimes	Copies	of the materials listed are attached (except for the foregoing).		
			~		

Non-English Language References				
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).		
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:		
		X = Y =	document of particular relevance when it is taken alone document of particular relevance when it is combined with another such document	
		A =	document defining the general state of the art	
		O =	non-written disclosure	
		P =	intercalated document	
		T =	document cited to understand the theory or principle underlying the invention	
		E =	patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date	
		D =	cited in the application	
		L =	cited for another reason	
		& =	publication of member of same patent family	
		Transla	ation of other relevant information on foreign search report	
		[insert	necessary translation here]	
Payme	nt of Fe	es Due	(If Any):	
	A chec	k for \$_	covering the fee identified above is attached.	
	Please	charge	to Deposit Account No. 13-3402 \$ for the fee identified above.	

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

James E. Ruland, Reg. No. 37,432 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.
Arlington Courthouse Plaza 1
2200 Clarendon Blvd. Suite 1400
Arlington, Virginia 22201
Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MAIKO-0037

Date: 15 March 2005

JER:jqs

K:\MAIKO\37\Information Disclosure Statement 3-14-05.doc

AAAB	4	-	2000
MAR	- 1	כ	ZUUD

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persona green and personal to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use a	as many	sneets	as ne	cessary)	

	Complete if Known	•
Application Number	10/647,438	
Filing Date	8/26/03	
First Named Inventor	TAS	
Group Art Unit	1755	
Examiner Name	Manlove, Shalie A.	
Attorney Docket Number	MAIKO-0037	

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	A1	HUIPIN YUAN et al., "Tissue responses of calcium phosphate cement: a study in dogs", ELSEVIER Biomaterials 21 (2000) pgs. 1283-1290	·
			,
	<u> </u>		

Examiner Signature	Date Considered	
	Oorisidered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.